|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...2526272829303132333435...3940» |
- | agomelatine / Generic mfg.
New P4 trial: Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) (clinicaltrials.gov) - Mar 31, 2013
P4, N=27, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
- Trial completion: Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital (clinicaltrials.gov) - Mar 31, 2013
P=N/A, N=99, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed
- Trial completion: Psychosocial Training for Pediatric Health Care Providers (clinicaltrials.gov) - Mar 31, 2013
P=N/A, N=350, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia (clinicaltrials.gov) - Mar 30, 2013
P=N/A, N=146, Completed, Sponsor: Prague Psychiatric Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| lurasidone / Generic mfg.
New P3 trial: Lurasidone Low-Dose - High-Dose Study Study (clinicaltrials.gov) - Mar 28, 2013
P3, N=400, Active, not recruiting, Sponsor: Sunovion
- Trial completion: Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia (clinicaltrials.gov) - Mar 27, 2013
P1, N=66, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis (clinicaltrials.gov) - Mar 27, 2013
P=N/A, N=46, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Recruiting --> Completed
- Trial withdrawal: Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Mar 26, 2013
P2, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment change: Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Mar 26, 2013
P2, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Terminated --> Withdrawn N=135 --> 0
- Trial completion: Pharmacological Approach to Improve the Outcome of Social Cognition Training (clinicaltrials.gov) - Mar 26, 2013
P1, N=27, Completed, Sponsor: VA Greater Los Angeles Healthcare System
N=135 --> 0 Recruiting --> Completed
- Trial completion: Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia? (clinicaltrials.gov) - Mar 26, 2013
P=N/A, N=24, Completed, Sponsor: VA Greater Los Angeles Healthcare System
Recruiting --> Completed Recruiting --> Completed
- quetiapine extended-release / Generic mfg.
Trial termination, Monotherapy: Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms (clinicaltrials.gov) - Mar 25, 2013
P4, N=32, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Recruiting --> Terminated; AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012
- quetiapine extended-release / Generic mfg.
Enrollment change, Monotherapy: Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms (clinicaltrials.gov) - Mar 25, 2013
P4, N=32, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Terminated; AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012 N=80 --> 32
- |||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment open: Brexpiprazole in Patients With Acute Schizophrenia (clinicaltrials.gov) - Mar 25, 2013
P3, N=465, Recruiting, Sponsor: H. Lundbeck A/S
N=80 --> 32 Not yet recruiting --> Recruiting
- |||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment open: EQUATOR: Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia (clinicaltrials.gov) - Mar 24, 2013
P3, N=420, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial termination: NIC-PAS: Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia (clinicaltrials.gov) - Mar 21, 2013
P=N/A, N=20, Terminated, Sponsor: Centre for Addiction and Mental Health
Not yet recruiting --> Recruiting Recruiting --> Terminated; Limited staff and operating resources
- Enrollment change: SMI-DENTAL;SMIDENTIST-HMO-CTIL: Dental Status of Patients With Severe Mental Illness (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=80, Completed, Sponsor: Hadassah Medical Organization
Recruiting --> Terminated; Limited staff and operating resources N=200 --> 80
- Trial completion: SMI-DENTAL;SMIDENTIST-HMO-CTIL: Dental Status of Patients With Severe Mental Illness (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=80, Completed, Sponsor: Hadassah Medical Organization
N=200 --> 80 Recruiting --> Completed
- Enrollment change: Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia (clinicaltrials.gov) - Mar 18, 2013
P=N/A, N=179, Completed, Sponsor: Veterans Medical Research Foundation
Recruiting --> Completed N=240 --> 179
- olanzapine / Generic mfg.
Trial completion, Adverse events: Melatonin for Prevention of Metabolic Side Effects of Olanzapine (clinicaltrials.gov) - Mar 18, 2013
P2, N=36, Completed, Sponsor: Guilan University of Medical Sciences
N=240 --> 179 Recruiting --> Completed
- Trial completion: Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia (clinicaltrials.gov) - Mar 18, 2013
P=N/A, N=179, Completed, Sponsor: Veterans Medical Research Foundation
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: SAFARI: Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=320, Recruiting, Sponsor: Karolinska Institutet
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| brilaroxazine (RP5063) / Reviva
Trial completion: RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Mar 15, 2013
P2, N=228, Completed, Sponsor: Reviva Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | JNJ-37822681 / J&J
New P2 trial: A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia (clinicaltrials.gov) - Mar 14, 2013
P2, N=33, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- iloperidone / Generic mfg.
Enrollment open: Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients (clinicaltrials.gov) - Mar 14, 2013
P1, N=29, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Suspended --> Recruiting
- olanzapine / Generic mfg.
Trial initiation date: Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (clinicaltrials.gov) - Mar 12, 2013
P4, N=25, Completed, Sponsor: Universit
Suspended --> Recruiting Initiation date: Sep 2005 --> Sep 2006
- New P4 trial: Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics (clinicaltrials.gov) - Mar 12, 2013
P4, N=50, Completed, Sponsor: Instituto Nacional de Psiquiatr
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: Brexpiprazole in Patients With Schizophrenia (clinicaltrials.gov) - Mar 12, 2013
P3, N=140, Recruiting, Sponsor: H. Lundbeck A/S
- |||| Fanapt LAI (iloperidone depot injectable formulation) / Vanda
Trial completion: Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients (clinicaltrials.gov) - Mar 12, 2013
P1/2, N=81, Completed, Sponsor: Novartis Pharmaceuticals
Initiation date: Sep 2005 --> Sep 2006 Terminated --> Completed
- olanzapine / Generic mfg.
Trial completion: Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (clinicaltrials.gov) - Mar 12, 2013
P4, N=25, Completed, Sponsor: Universit
Terminated --> Completed Recruiting --> Completed
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: Brexpiprazole in Patients With Acute Schizophrenia (clinicaltrials.gov) - Mar 11, 2013
P3, N=465, Recruiting, Sponsor: H. Lundbeck A/S
- cannabidiol/delta-9-tetrahydrocannabivarin (GW42004) / Jazz
Trial termination: Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine (clinicaltrials.gov) - Mar 10, 2013
P2, N=2, Terminated, Sponsor: GW Pharmaceuticals Ltd.
Recruiting --> Completed Recruiting --> Terminated; The Chief Investigator and the Sponsor have concluded that it will not be possible to complete the enrolment in any meaningful timeframe.
- cannabidiol/delta-9-tetrahydrocannabivarin (GW42004) / Jazz
Enrollment change: Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine (clinicaltrials.gov) - Mar 10, 2013
P2, N=2, Terminated, Sponsor: GW Pharmaceuticals Ltd.
Recruiting --> Terminated; The Chief Investigator and the Sponsor have concluded that it will not be possible to complete the enrolment in any meaningful timeframe. N=60 --> 2
- Enrollment change: Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia (clinicaltrials.gov) - Mar 10, 2013
P1, N=80, Recruiting, Sponsor: University of North Carolina, Chapel Hill
N=60 --> 2 N=54 --> 80
- | minocycline / Generic mfg.
New P4 trial: MINOS: Minocycline for Schizophrenia (clinicaltrials.gov) - Mar 10, 2013
P4, N=150, Not yet recruiting, Sponsor: Addis Ababa University
- ||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment change: A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia (clinicaltrials.gov) - Mar 3, 2013
P2, N=56, Completed, Sponsor: Janssen Pharmaceutical K.K.
N=54 --> 80 N=73 --> 56
- Enrollment open: Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=30, Recruiting, Sponsor: Charite University, Berlin, Germany
N=73 --> 56 Not yet recruiting --> Recruiting
- Enrollment open: The Family Cognitive Adaptation Training Manual: A Test of Effectiveness (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=40, Recruiting, Sponsor: Centre for Addiction and Mental Health
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: MEMENTA: Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=600, Recruiting, Sponsor: Technische Universit
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- |||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Enrollment open: Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia (clinicaltrials.gov) - Feb 28, 2013
P3, N=286, Recruiting, Sponsor: H. Lundbeck A/S
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| ADX71149 / J&J, Addex
Trial completion, Monotherapy: Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (clinicaltrials.gov) - Feb 28, 2013
P2, N=100, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Enrollment change: Huperzine for Cognitive and Functional Impairment in Schizophrenia (clinicaltrials.gov) - Feb 27, 2013
P2, N=56, Completed, Sponsor: Biomedisyn Corporation
Recruiting --> Completed N=96 --> 56
- |||| Trial completion: Huperzine for Cognitive and Functional Impairment in Schizophrenia (clinicaltrials.gov) - Feb 27, 2013
P2, N=56, Completed, Sponsor: Biomedisyn Corporation
N=96 --> 56 Recruiting --> Completed
- bitopertin (DISC-1459) / Disc Medicine
Trial completion: A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia (clinicaltrials.gov) - Feb 24, 2013
P2, N=301, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Completed
- || Enrollment change: REST: Relative Effectiveness of Schizophrenia Therapy Study (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=1110, Completed, Sponsor: Medco Health Solutions, Inc.
Recruiting --> Completed N=2000 --> 1110
- Clinical: Effects of Systematic Patient Feedback on Therapy Outcome (clinicaltrials.gov) - Feb 19, 2013
P=N/A, N=120, Recruiting, Sponsor: Norwegian University of Science and Technology
- | valacyclovir / Generic mfg.
New P4 trial: Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (clinicaltrials.gov) - Feb 18, 2013
P4, N=156, Enrolling by invitation, Sponsor: University of Pittsburgh
- ||||| amisulpride / Generic mfg.
New P4 trial: Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia (clinicaltrials.gov) - Feb 18, 2013
P4, N=304, Completed, Sponsor: Sanofi
- |||||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P3 trial: Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia (clinicaltrials.gov) - Feb 18, 2013
P3, N=286, Recruiting, Sponsor: H. Lundbeck A/S
- Bydureon (exenatide XR once-weekly) / AstraZeneca
New P3 trial: TAO: Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue (clinicaltrials.gov) - Feb 14, 2013
P3, N=50, Recruiting, Sponsor: Bjorn H. Ebdrup